SPARQL
Query
Update
Search
Quick
Advanced
Co-occurrence
RelFinder
About
Sources
Admin
System Info
Repository Management
Search Configuration
Sources
20679089
Source:
http://linkedlifedata.com/resource/pubmed/id/20679089
Search
Subject
(
51
)
Predicate
Object
All
Download in:
JSON
RDF
N3/Turtle
N-Triples
Switch to
Custom View
Named Graph
All
UniProt
NCBIGene
DrugBank
ClinicalTrials
UMLS
PubMed
Mappings
MentionedEntities
Language
All
English
Español
Português
Français
Deutsch
Русский
日本語
Български
Inference
Explicit and implicit
Explicit only
Implicit only
Statements in which the resource exists as a subject.
Predicate
Object
rdf:type
pubmed:Citation
lifeskim:mentions
umls-concept:C0035328
,
umls-concept:C0087111
,
umls-concept:C0205225
,
umls-concept:C0796392
,
umls-concept:C1274040
pubmed:issue
8
pubmed:dateCreated
2010-8-3
pubmed:abstractText
The purpose of this study is to evaluate the efficacy of intravitreal bevacizumab as the primary treatment of macular oedema due to retinal vein occlusions.
pubmed:language
eng
pubmed:journal
http://linkedlifedata.com/resource/pubmed/journal/0421041
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Angiogenesis Inhibitors
,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal
,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized
,
http://linkedlifedata.com/resource/pubmed/chemical/VEGFA protein, human
,
http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor A
,
http://linkedlifedata.com/resource/pubmed/chemical/bevacizumab
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1468-2079
pubmed:author
pubmed-author:ArruabarrenaCC
,
pubmed-author:ContrerasII
,
pubmed-author:FigueroaM SMS
,
pubmed-author:NovalSS
pubmed:issnType
Electronic
pubmed:volume
94
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1052-6
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:20679089-Aged
,
pubmed-meshheading:20679089-Angiogenesis Inhibitors
,
pubmed-meshheading:20679089-Antibodies, Monoclonal
,
pubmed-meshheading:20679089-Antibodies, Monoclonal, Humanized
,
pubmed-meshheading:20679089-Female
,
pubmed-meshheading:20679089-Follow-Up Studies
,
pubmed-meshheading:20679089-Humans
,
pubmed-meshheading:20679089-Macular Edema
,
pubmed-meshheading:20679089-Male
,
pubmed-meshheading:20679089-Middle Aged
,
pubmed-meshheading:20679089-Prospective Studies
,
pubmed-meshheading:20679089-Retinal Vein Occlusion
,
pubmed-meshheading:20679089-Treatment Outcome
,
pubmed-meshheading:20679089-Vascular Endothelial Growth Factor A
,
pubmed-meshheading:20679089-Visual Acuity
pubmed:year
2010
pubmed:articleTitle
Results of bevacizumab as the primary treatment for retinal vein occlusions.
pubmed:affiliation
Department of Ophthalmology, Hospital Universitario Ramón y Cajal, c/ Ferraz, n degrees 35, 2 degrees Izquierda, 28008 Madrid, Spain.
pubmed:publicationType
Journal Article
,
Clinical Trial